Transcatheter Aortic Valve Replacement Market Size & Share, by Procedure (Transfemoral Approach, Transapical Approach, Transaortic Approach); Material; End use; Valve Type; Product; Indication - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Transcatheter Aortic Valve Replacement Market - Regional Analysis

North America Market Insights

The North America is dominating the transcatheter aortic valve replacement market and is expected to hold the regional revenue share of 39.9% by the end of 2035. The region is characterized by mature adoption, established reimbursement frameworks, and concentrated procedure volumes in high-tier cardiac centers. The United States leads with a well-defined Medicare coverage infrastructure, while Canada operates through provincial health authority tenders and centralized procurement. Private payer policies in the U.S. increasingly mirror public coverage determinations, creating a unified demand signal. In Canada, waitlist pressures for surgical replacement continue to drive provincial expansion of TAVR capacity. Both countries face margin compression as procurement models evolve from fee-for-device to episode-based bundled payments.

The rising procedure volumes and increasing treatment adoption for severe aortic stenosis is shaping the transcatheter aortic valve replacement market in the U.S. According to the SEC 2024 data, approximately 73,000 patients underwent TAVR procedures in the U.S., reflecting substantial year-over-year growth since the procedure was first introduced. The increasing number of eligible patients, combined with broader physician acceptance and expanding hospital capabilities, is strengthening demand for TAVR systems. Furthermore, industry estimates cited by FMI project that the global market opportunity associated with severe aortic stenosis and valve-in-valve (ViV) procedures could reach USD 12.4 billion by 2028, indicating significant long-term growth potential for the U.S. market.

The expanding utilization of the publicly funded healthcare system is driving the transcatheter aortic valve replacement market in Canada. According to the NLM study published in December 2022, nearly 4,145 Ontario patients underwent TAVR, reflecting the increasing role of TAVR as the standard treatment for severe aortic stenosis across multiple risk categories. The study also noted that TAVR has been publicly funded in Ontario and is available at all 11 cardiac surgery hospitals in the province. Researchers highlighted that rising demand for TAVR has been accompanied by policy discussions focused on improving equitable access and reducing post-procedure readmissions, factors expected to support continued market expansion in Canada.

APAC Market Insights

The Asia Pacific is projected to emerge rapidly during the assessed period, 2026 to 2035 in the transcatheter aortic valve replacement market. The region is highly heterogeneous, with Japan and Australia representing mature, regulated markets, while China, India, and Southeast Asian nations exhibit rapid but fragmented adoption. Reimbursement structures vary widely: Japan operates under a national fee schedule, India relies on mixed public-private insurance, and most of Southeast Asia remains out-of-pocket dominant. Key drivers include aging populations, rising prevalence of bicuspid aortic valve disease, and government initiatives to establish structural heart programs in tier-two cities. Local manufacturing partnerships and cost-engineered valve platforms are emerging as necessary strategies for volume penetration.

The transcatheter aortic valve replacement market in India is gaining momentum as clinical evidence demonstrates favorable outcomes in patients with severe aortic stenosis, a condition whose prevalence rises from 2.8% among individuals aged 60–74 years to 13.1% in those older than 75 years. Data published in the NLM study in February 2022 reported that 84 intermediate- and high-risk patients underwent TAVR between 2017 and 2021 at two Armed Forces cardiac centers, highlighting the gradual expansion of advanced structural heart interventions in the country. The study showed a procedural success rate exceeding 90%, with procedural mortality of only 2.3%, reinforcing physician confidence in catheter-based valve replacement. As India’s elderly population grows and specialized cardiac centers increase capacity, demand for TAVR procedures is expected to strengthen further.

The rising aging population and increasing prevalence of aortic stenosis (AS) is shaping the transcatheter aortic valve replacement market in China. According to a NLM study published in July 2024, AS affects more than 1% of the Chinese population aged 65 years and older, creating a substantial patient pool for valve replacement therapies. The study reported that the number of TAVR procedures in China increased from 293 in 2017 to 7,357 in 2021, demonstrating strong adoption of minimally invasive valve interventions. China’s growing structural heart market is further supported by the availability of multiple domestically developed transcatheter valves alongside internationally recognized devices. With approximately 16% of China’s population aged 60 years or older, demand for TAVR is expected to continue rising as healthcare providers expand access to advanced cardiac treatments.

Europe Market Insights

The Europe transcatheter aortic valve replacement market is characterized by cross-country reimbursement diversity, with Germany, France, and Italy leading in procedure volumes, while Eastern European nations remain underpenetrated. The European Medicines Agency provides centralized device approval, but national health technology assessment bodies independently determine pricing and coverage. Key dynamics include volume-based procurement in France, DRG tariff modernization in Germany, and NHS waiting list reduction targets in the United Kingdom. Manufacturers face pressure to demonstrate long-term durability data (10+ years) to secure favorable pricing. Consolidation among hospital heart teams is accelerating, with regional referral networks concentrating TAVR volumes in high-volume centers. Cost containment initiatives across Southern Europe are driving demand for second-generation, lower-cost valve platforms.

The adoption of innovative valve technologies and expansion into new patient populations is shaping the transcatheter aortic valve replacement market in Germany. A multicenter registry involving 58 consecutive patients across six German cardiac centers evaluated the commercial use of the CE-marked JenaValve Trilogy system for severe symptomatic aortic regurgitation. The NLM August 2023 study reported a 98% device success rate and a low 30-day mortality rate of 1.7%, demonstrating strong procedural outcomes in patients considered unsuitable for surgery. Additionally, 92% of patients achieved NYHA Class I or II status within 30 days, indicating significant functional improvement. These favorable results support broader utilization of transcatheter valve therapies in Germany and reinforce the country’s position as a leading European market for structural heart interventions and advanced TAVR technologies.

The transcatheter aortic valve replacement market in the UK is benefiting from strong clinical evidence and government-backed research supporting wider adoption of minimally invasive valve replacement procedures. The National Institute for Health and Care Research (NIHR)-funded UK-TAVI trial included all 34 TAVI centers across the United Kingdom and enrolled 890 patients aged 70 years and older with a median age of 81 years. The NLM September 2022 study found that 1-year all-cause mortality was 4.6% in the TAVI group compared with 6.6% following surgical aortic valve replacement (SAVR), confirming TAVI as a non-inferior treatment option. Additionally, the median hospital stay was significantly shorter with TAVI (3 days versus 8 days for SAVR), supporting healthcare efficiency objectives and encouraging continued expansion of TAVI services across the UK healthcare system.